Szela Mary T
SEC-identified person · CIK 1410289 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Absci Corp ABSI | Director | filed 2025 - 2026 |
| Zeta Acquisition Corp III KURO | Director | filed 2018 - 2026 |
| Trisalus Life Sciences, Inc. TLSI | Director · CEO and President | filed 2023 - 2026 |
| Averin Capital Acquisition Corp. ACAAU | Director | filed 2026 - 2026 |
| Omega Therapeutics, Inc. OMGA | Director | filed 2021 - 2024 |
| Prometheus Biosciences, Inc. RXDX | Director | filed 2021 - 2023 |
| Coherus Oncology, Inc. CHRS | Director | filed 2014 - 2021 |
| Alimera Sciences INC ALM | Director | filed 2018 - 2020 |
| QLT INC/BC QLTI | Director · Chief Executive Officer | filed 2016 - 2017 |
| Aegerion Pharmaceuticals, Inc. AEGR | Director · Chief Executive Officer | filed 2016 - 2016 |
| Receptos, Inc. RCPT | Director | filed 2014 - 2015 |
| Abbott Laboratories ABT | Senior Vice President | filed 2007 - 2011 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.